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Abstract
OBJECTIVES—To report anatomic and functional outcomes 2 years after sacrocolpopexy in stress-
continent women with or without prophylactic Burch colposuspension.
METHODS—In the Colpopexy and Urinary Reduction Efforts (CARE) trial, stress-continent
women undergoing sacrocolpopexy were randomized to receive or not receive a Burch
colposuspension. Outcomes included urinary symptoms, other pelvic symptoms, and pelvic support.
Standardized pelvic organ prolapse quantification examinations and validated outcome measures
including the Pelvic Floor Distress Inventory and the Pelvic Floor Impact Questionnaire were
completed before surgery and at several postoperative intervals, including at 2 years.
RESULTS—This analysis is based on 302 of 322 randomized participants. Most were Caucasian
(94%), with a mean age of 62±10 years (mean±standard deviation). Two years after surgery, 32.0%
and 45.2% of women in the Burch and control groups, respectively, met the stress incontinence
endpoint (presence of symptoms or positive cough stress test or interval treatment for stress
incontinence, P=.026). The apex was well supported (point C within 2 cm of total vaginal length) in
95% of women, and this was not affected by concomitant Burch (P=.18). There was a trend toward
fewer urgency symptoms in the Burch group (32.0% versus 44.5% no Burch, P=.085). Twenty
participants experienced mesh or suture erosions.
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CONCLUSION—The early advantage of prophylactic Burch colposuspension for stress
incontinence that was seen at 3 months remains at 2 years. Apical anatomic success rates are high
and not affected by concomitant Burch.
The Colpopexy and Urinary Reduction Efforts (CARE) study wasconductedto estimatethe
utility of Burch colposuspension at the time of sacrocolpopexy in stress-continent women. The
short-term protective benefit of concomitant Burch colposuspension on bladder symptoms up
to 1 year has been described.1,2 Recent evidence suggests that the Burch colposuspension is
less effective than a rectus fascial sling to treat stress incontinence symptoms in women with
and without prolapse3 and that the efficacy of both studied procedures decreases over the initial
2 years after surgery. To provide longer term information about the optimal strategy for
minimizing bothersome bladder symptoms at the time of prolapse surgery, the CARE trial
included a 2-year assessment. In addition, concomitant colposuspension can affect vaginal
support, an effect best appreciated over time.
The aims of this report are to compare, between women who did and did not undergo Burch
colposuspension at the time of sacrocolpopexy, bladder, functional, sexual, and anatomical
outcomes 2 years after the index surgery and to report complications related to surgery over
the 2-year period.
MATERIALS AND METHODS
We previously reported the CARE trial methods4 and 3-month1 and 1-year outcomes of
bladder symptoms.2 This trial was registered and received institutional review board approval
at all participating sites before enrollment of women planning sacrocolpopexy for stage II–IV
prolapse without symptoms of stress incontinence between March 7, 2002 and February 7,
2005. To be eligible, participants had to be categorized as stress continent based on their
responses of “never” or “rarely” to the six questions of the Medical, Epidemiological, and
Social Aspects of Aging (MESA) questionnaire, which focus on stress incontinence symptoms.
5
Participants were assigned with equal probability to sacrocolpopexy with or without
prophylactic Burch colposuspension using computer-generated random numbers in blocks of
varying sizes and stratified by surgeon and intent to perform paravaginal repair (done at the
surgeon’s discretion and disclosed before randomization). Surgical materials and techniques
for the Burch colposuspension were standardized; other surgical materials were left to surgeon
discretion. Participants, research staff, and telephone interviewers were masked to assignment
for a minimum of 3 months, with the intent of maintaining masking for 2 years after surgery.
Outcome measures included anatomical measures (Q-tip test, Pelvic Organ Prolapse
Quantified [POP-Q] staging, and standardized stress test), pelvic floor disorder symptoms and
impact measures (MESA Questionnaire,5 Incontinence Severity Index,6 Pelvic Floor Distress
Inventory [PFDI], Pelvic Floor Impact Questionnaire,7 Pelvic Organ Prolapse/Urinary
Incontinence Sexual Questionnaire,8,9 SF-36 Version 2,10 and patient satisfaction items), and
adverse events. Research nurses assessed anatomical measures at 3 months, 1 year, and 2 years.
Trained interviewers conducted quality of life interviews by telephone at 3, 6, 12, and 24
months. Instruments were reliable for use by telephone interview.11 We aimed to maintain
blinding until our primary outcome at 3 months. At 2 years, 123 participants (Burch 59, control
64) reported that they became unblinded. Group assignment was identified correctly in 48
Burch and 44 control participants, incorrectly in 1 Burch and 10 control participants. The
remaining participants stated that they did not know their group assignment.
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The primary outcome, as previously reported, was stress incontinence at the 3-month
assessment point.1 Participants were characterized as having stress incontinence if any of the
following were present:
1. Symptoms, as defined by a “yes” response to any of three questions in the PFDI stress
incontinence subscale assessing leakage with coughing, sneezing, or laughing;
physical exercise; and lifting or bending over
2. Stress incontinence during a standardized stress test at maximum bladder capacity or
300 mL, whichever was less
3. Any treatment for stress incontinence after the study surgery
A symptom recorded on the PFDI was considered bothersome when participants reported
“moderate” or “quite a bit” of bother. Participants met our “urge endpoint” when they reported
bothersome urge incontinence, urgency, frequency, nocturia, or enuresis, or if they reported
treatment for urge incontinence after the index surgery. Stress and urge symptoms also were
assessed using the stress subscale and the irritative voiding subscale of the PFDI, respectively.
A higher score represents more symptoms and bother.
Serious adverse events were defined as untoward medical occurrences that were life-
threatening or resulted in death or that required hospitalization or prolonged hospitalization
for the index surgery, any condition that resulted in persistent or significant disability, or any
other important medical condition. Serious adverse events were categorized by the body system
affected, such as gastrointestinal or urogenital. Because surgical treatment for stress
incontinence was a component of the stress endpoint, this was not included among the adverse
events.
The Pelvic Floor Disorders Network’s independent Data and Safety Monitoring Board
recommended that enrollment stop when 3-month results of the first of two planned interim
analyses became available. Significance levels were adjusted to account for the interim
analysis. Data were analyzed by a central data-coordinating center using SAS (Cary, NC). The
groups were compared at baseline by age, body mass index, and prolapse stage; subsequent
analyses were not adjusted for these measures because they were similar in both groups.
Proportions were compared using Mantel-Haenszel χ2 statistic adjusted for surgeon and
paravaginal repair. Quality of life measures were compared using a general linear model with
the same covariates (surgeon, paravaginal repair). Numbers do not necessarily total the entire
sample size because not all participants completed every aspect of data collection; 10
participants in each treatment group withdrew without having been retreated for either stress
urinary incontinence (SUI) or prolapse.
Antiincontinence surgery (including bulking agents) or repeat prolapse surgery could affect
the outcomes at the postoperative assessments. To ensure that we did not enhance results, we
imputed values for the quality of life responses occurring after retreatment by using the more
negative (worse) response of either the interview after retreatment or the previous observation
carried forward. In this way, we tried to eliminate responses that were good specifically because
the participant underwent retreatment for incontinence or prolapse. In the three cases in which
retreatment occurred before the 3-month interview, we still used the 3-month interview results.
Ten participants in each group withdrew before 24 months without reporting any retreatment;
these participants are not included in the 24-month analysis. Similarly, the earlier analyses do
not include participants who withdrew before the time of the analysis (3 months or 12 months)
without reporting any retreatment. All tests performed and Pvalues reported were two-tailed.
Results are presented as percentages or as mean±standard deviation.
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Of 322 women enrolled and randomized, 157 underwent Burch procedure with abdominal
sacrocolpopexy and 165 were controls (abdominal sacrocolpopexy without Burch). Seventy
percent had prior hysterectomy. Most participants were Caucasian (94%), with a mean age of
62±10 years (mean±standard deviation). There were no significant differences between the
groups in baseline characteristics, and these characteristics are similar to those reported in the
primary paper.1
Three hundred two of the 322 randomized participants completed some part of the 2-year
assessment or were treated for SUI after study surgery; 250 completed all outcome measures
(cough stress test, physical examination, and quality of life and symptom instruments), and 52
completed only quality of life and symptom assessment. The noncompleters did not differ
significantly between groups.
The primary outcome measures for this study are summarized in Table 1. To demonstrate the
effect of imputation, two sets of results are presented for three of the outcome measures—the
results without imputation and then the results with imputation. Nine participants in the Burch
group had treatment for either stress incontinence or prolapse, whereas 20 participants in the
control group had one of these treatments. Therefore, the results in the control group are more
affected by the imputation. Using the imputed data, women in the Burch group had a lower
rate of the overall stress incontinence endpoint (Burch 32.0% versus control 45.2%, P=.026),
lower bothersome SUI (Burch 11.6% versus control 25.2%, P=.004), and a trend toward a
lower rate of the urge endpoint (Burch 32.0% versus control 44.5%, P=.085).
The anatomical outcomes, based on the Pelvic Organ Prolapse Quantified evaluation, are
shown in Table 2. Two years after surgery, the apex was well supported (point C within 2 cm
of total vaginal length) in 95% of women, and this was not affected by concomitant Burch
(P=.18). As expected, the anterior wall was slightly higher and the posterior wall slightly lower
in the Burch group compared with the control group.
Results of other validated outcome measures are shown in Table 3. The Burch group had less
SUI bother and less incontinence severity. There were no other statistically significant
differences between the groups in terms of symptom bother, symptom impact, or sexual
function, although there were trends toward improvement in all bladder measures in the Burch
group. We did not detect any differences between SF-36 results or health utility scores 2 years
after surgery.
Most women were satisfied with their treatment. The mean scores for the question, “In your
opinion, has the treatment of your pelvic floor condition been … ” (scale of 1–5, 1=very
successful) were 1.37±0.71 and 1.48±0.78 in the Burch and control groups, respectively. The
mean scores for the question, “Compared to how you were before your pelvic floor operation,
would you say that now you are … (scale of 1–5, 1=much better) were 1.22±0.67 and 1.34
±0.86 in the Burch and control groups, respectively.
Complications related to the surgery are summarized in Table 4. Whereas some complications,
such as ileus or small bowel obstruction and wound problems, were most common during the
initial postoperative period, others, such as incisional hernias and mesh erosion, continued to
be reported during the second year after surgery. Most women with ileus or small bowel
obstruction were treated successfully with intravenous fluids and bowel rest; the four who
returned to the operating room for treatment did so 3, 4, 10, and 163 days after surgery. Within
2 years, four patients experienced deep vein thrombosis or pulmonary embolism, including
one such complication during transvaginal mesh removal. At this time, 20 women have been
diagnosed with complications from surgical materials (mesh, sutures, or both), although not
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all have undergone treatment. Eight women have undergone reoperation for prolapse—four in
the posterior compartment, one in the anterior compartment, one in both the anterior and
posterior compartments, and two in the apical compartment.
DISCUSSION
The effectiveness of a prophylactic Burch colposuspension at the time of sacrocolpopexy in
stress-continent women remains at 2 years, with decreased SUI bother, decreased SUI severity,
and a trend toward improvement in urge outcomes. Because approximately 1 in 10 women in
the Burch group still reported bothersome SUI, it is tempting to suggest an alterative
prophylactic procedure. Investigators from the Urinary Incontinence Treatment Network
recently reported a randomized trial demonstrating that, in women with SUI, the Burch
colposuspension results in fewer objective SUI cures compared with the fascial sling.3
However, this trial does not provide evidence that the same is true in the setting of
transabdominal prolapse surgery.
Our results clearly demonstrate that sacrocolpopexy has a beneficial role in reducing
bothersome irritative and obstructive urinary symptoms after surgery, regardless of
concomitant Burch. This finding suggests that prolapse repair itself has a beneficial effect on
certain urinary symptoms. Multiple geographic sites and multiple surgeons increase the
generalizability of our findings and are an important strength of our study. Differences in
nomenclature, preoperative testing conditions, and diagnostic terms limit comparisons of our
study with prior small case series. In one retrospective study of women undergoing
sacrocolpopexy, a Burch procedure was done in all participants whether incontinent or not.
12 Thirty-three of 47 (70%) were continent and 14 (30%) incontinent preoperatively. The
authors reported that all participants remained continent at a mean of 34 months
postoperatively. Similarly, Lefranc et al13 performed a Burch colposuspension in all women
undergoing sacrocolpopexy. About 10 years later, no patients who previously had been
continent and underwent a prophylactic Burch developed de novo SUI; however, 23 of the 57
initially incontinent patients had recurrent SUI despite the Burch, four within the first year,
five after 1 year, 11 at 5 years, two at 10 years, and one at 15 years.
Our results and those few studies addressing stress-continent women at the time of
sacrocolpopexy suggest that an incontinence procedure does provide benefit, does not result
in adverse side effects, and should be recommended at the time of sacrocolpopexy. The risk/
benefit ratio of other procedures can be explored in future randomized surgical trials.
Sacrocolpopexy is known to have high apical success rates.14 Our apical success rate of 95%
is consistent with those findings, regardless of whether concomitant Burch was performed. In
this trial, surgeons could choose whether or not to repair all anterior and posterior defects. The
proportion of women with stage II prolapse at 24 months represents, in part, these surgical
decisions rather than surgical failure of an operated compartment. Some investigators have
suggested that the Burch colposuspension challenges apical and posterior support. This effect
also has been noted at the time of laparoscopic sacrocolpopexy with concomitant Burch.15,
16 Although we detected a statistical difference in the mean position of points Ba and Bp, we
do not believe that these differences are clinically significant. However, eight patients
underwent subsequent prolapse surgery for the anterior or posterior vaginal compartments.
In the existing literature, the median overall short-term rate of mesh erosion was 3.4% with a
range of 0–5% for all mesh types.14 Our rate of foreign body complications, including both
sutures and mesh, is at the upper end of this range and likely reflects the careful follow-up of
this patient population. Clearly, the occurrence of mesh erosions is not limited to the immediate
postoperative setting,17 and longer term follow-up is important to determine what type of mesh
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and which type of patient remain at risk. Other adverse events are within previously reported
prevalence rates.
Two years after surgery, we found that the majority of patients were satisfied, overall, with
their surgeries and symptom control. This satisfaction corresponds to the overall improvement
in lower urinary tract and prolapse symptoms, sexual function, and effect on symptom-specific
and overall quality of life after the prolapse surgery. The findings in our study should be
extrapolated with caution to other prolapse procedures and/or other continence procedures.
Many of these participants have agreed to continued longitudinal observation so that we can
determine characteristics of those patients predisposed to recurrent symptomatic prolapse,
foreign body complications, and other pelvic floor abnormalities.
Sacrocolpopexy with concomitant Burch colposuspension confers sustained lower urinary tract
symptom improvement with improvement of stress incontinence symptoms and no clinically
significant deleterious effects due to the colposuspension. Based on these results, we propose
that a prophylactic Burch colposuspension should be recommended at the time of
sacrocolpopexy for stress-continent women who have a mobile urethra.
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